Mycovia Pharmaceuticals

What Mycovia Pharmaceuticals does

Mycovia Pharmaceuticals is a privately held, clinical-stage-to-commercial biopharmaceutical company headquartered in Durham, North Carolina, founded in 2018. The company is focused on developing and commercializing antifungal therapies for underserved indications in women's health and infectious disease. Its sole commercial asset is VIVJOA (oteseconazole), a first-in-class oral azole antifungal that received FDA approval in 2022 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a condition with historically limited therapeutic options. The clinical data package supporting VIVJOA includes the Phase 3 VIOLET studies, with 2-year extension results published in November 2025 reinforcing long-term recurrence-free efficacy.

The company's business model is a capital-light, single-product specialty pharma structure. In the US, commercialization flows through an exclusive distribution agreement with AllianceRx Walgreens Prime signed in March 2024, which concentrates revenue through a single specialty pharmacy channel. Internationally, Mycovia has licensed Greater China rights to Jiangsu Hengrui Pharmaceuticals (2019); oteseconazole received NMPA approval in June 2023 and was added to China's National Reimbursement Drug List in 2024, generating royalty revenue without local infrastructure investment. The company is also pursuing a second indication, having initiated a Phase 2 study of oteseconazole for cryptococcal meningitis in June 2025, which represents pipeline diversification beyond the RVVC franchise. Mycovia has not disclosed funding rounds or revenue, and operates with a small (11-50 employee) organization led by CEO Patrick Jordan.

Name

Mycovia Pharmaceuticals

Legal name

Mycovia Pharmaceuticals, Inc.

Website

https://mycovia.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Mycovia Pharmaceuticals is a Durham, NC-based private biopharmaceutical company founded in 2018 that develops and commercializes antifungal therapies, with its sole FDA-approved product VIVJOA (oteseconazole) indicated for recurrent vulvovaginal candidiasis in women.

Ownership category

akta.pro rank

Product category

Antifungal Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antifungal therapeutics
• Women's health pharmaceuticals
• Prescription pharmaceuticals
• Vulvovaginal candidiasis treatment
• Biopharmaceutical development

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical product sales (VIVJOA): Revenue generated from sales of prescription VIVJOA (oteseconazole) capsules in the US market, distributed through specialty pharmacies including AllianceRx Walgreens Pharmacy.
2. Licensing royalties (Jiangsu Hengrui Pharmaceuticals): Mycovia receives licensing royalties from Jiangsu Hengrui Pharmaceuticals for the development and commercialization of oteseconazole in China (mainland China, Hong Kong, Macau, and Taiwan). Hengrui received approval from China's National Medical Products Administration in June 2023, and VIVJOA was included in China's National Reimbursement Drug List in 2024.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Mycovia Pharmaceuticals develops and commercializes VIVJOA (oteseconazole capsules), a first-in-class oral antifungal medication containing 150 mg oteseconazole per capsule, approved by the FDA for the treatment of vulvovaginal candidiasis (VVC), including severe VVC and recurrent VVC. The company distributes VIVJOA through specialty pharmacies in the US and licenses it to Jiangsu Hengrui Pharmaceuticals for commercialization in China.

Product overview

Mycovia Pharmaceuticals is a biopharmaceutical company with a single commercial product - VIVJOA (oteseconazole capsules). The company focuses on developing novel therapies to address unmet needs in women's health and other overlooked medical conditions. VIVJOA is a first-in-class antifungal medication approved for the treatment of vulvovaginal candidiasis (VVC), including severe VVC and recurrent VVC.

Differentiator

Problem solved

Functional benefit

Brands

• VIVJOA: VIVJOA (oteseconazole capsules) 150 mg per capsule, for oral use - FDA-approved treatment for severe vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC).

Products and services

• VIVJOA (oteseconazole capsules) VIVJOA is a first-in-class oral antifungal medication containing 150 mg oteseconazole per capsule, approved by the FDA for the treatment of vulvovaginal candidiasis (VVC) in women, including severe VVC and recurrent VVC (RVVC). It is distributed in the US through AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies and is licensed to Jiangsu Hengrui Pharmaceuticals for the China market.

Quantifiable outcome

• 2-year efficacy results from VIOLET Phase 3 extension studies published in Journal of Women's Health (November 2025)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• AllianceRx Walgreens Pharmacy and Walgreens Community-based Specialty PharmaciescoreChannel Partner/ Reseller/ Distributor · 26 March 2024Mycovia announced AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies as the exclusive distributor of VIVJOA in the US market. This partnership provides broad accessibility for patients through Walgreens' specialty pharmacy network.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 January 2019Mycovia partnered with Jiangsu Hengrui Pharmaceuticals in an exclusive agreement to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau, and Taiwan. In June 2023, VIVJOA (Oteseconazole Capsules, 150 mg) received approval in China from the National Medical Products Administration and is indicated for the treatment of severe VVC. The drug was included in China's National Reimbursement Drug List in 2024 due to its first-in-class therapy status.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Scynexis (now part of GSK): Developed Brexafemme (ibrexafungerp), a competing first-in-class antifungal also positioned for VVC/RVVC. Direct head-to-head competitor to Mycovia's oteseconazole in the same indication, patient population, and prescribing channel.
• Evofem Biosciences: Specialty women's health biopharma commercializing Phexxi (vaginal pH modulator) for women's reproductive health. Comparable as a small specialty pharma focused on under-addressed OB-GYN conditions and operating through similar GTM motions.

Emerging players

• Daré Bioscience: Clinical-stage women's health biopharma with a pipeline focused on contraception, fertility, and vaginal health. Comparable as a small public women's-health specialty therapeutics company targeting similar OB-GYN prescribers.

Broad incumbents

• TherapeuticsMD (a Bayer company): Women's health specialty pharma (acquired by Bayer) with branded OB-GYN products. Comparable as a commercial-stage women's health therapeutics franchise with overlap in OB-GYN prescriber relationships and women's health go-to-market.
• Organon & Co. Global women's health-focused pharmaceutical company spun out of Merck, with an established OB-GYN commercial infrastructure and women's health product portfolio. Comparable as a scaled incumbent in women's health therapeutics distribution.
• Astellas Pharma: Large pharma with a significant antifungal franchise (Cresemba/isavuconazole and legacy amphotericin formulations). Comparable as an established innovator in invasive fungal disease treatment overlapping with Mycovia's antifungal focus.
• Pfizer: Major branded pharma with Diflucan (fluconazole), the dominant legacy azole antifungal used in VVC, plus a women's health franchise. Comparable as the incumbent whose off-patent azole is the main therapeutic substitute Mycovia must displace.
• Merck & Co. Large pharma with established antifungal portfolio (Noxafil/posaconazole) and the originator of women's health assets now housed at Organon. Comparable as a broad incumbent in invasive fungal disease therapeutics.
• Bayer Pharmaceuticals: Global pharma with an OB-GYN and women's health franchise (including acquired TherapeuticsMD assets). Comparable as a broad incumbent women'-s-health player with overlapping prescriber audience and reproductive-health commercialization muscle.

Others

• Hologic: Women's health-focused diagnostics and medical device company. Not a therapeutic competitor but adjacent — overlapping OB-GYN customer relationships and shared focus on women's health decision-makers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MycoviaPharma
• LinkedInlinkedin.com/company/mycovia-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mycovia Pharmaceuticals